timothy sykes logo

Stock News

Iovance Biotherapeutics Surges After Amtagvi Approval in Canada

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Ellis Hobbs Fact-checked by Matt Monaco
Updated 9/6/2025, 12:14 pm ET 9/6/2025, 12:14 pm ET | 5 min 5 min read
Iovance Biotherapeutics Surges After Amtagvi Approval in Canada Thumbnail

Iovance Biotherapeutics Inc. stocks have been trading up by 12.3 percent following positive market sentiment and promising clinical results.

Healthcare industry expert:

Analyst sentiment – neutral

Market Position & Fundamentals: Iovance Biotherapeutics (IOVA) is in a precarious market position, indicated by its negative profitability ratios, such as an EBIT margin of -161.4% and a gross margin of only 20.6%. Despite a reported revenue of $164.07 million, the enterprise’s net income remains significantly negative at -$111.66 million, reflecting inefficient management effectiveness with returns below industry averages—return on assets sits at -46.65%, and return on equity at -58.52%. Debt to equity is conservatively low at 0.08; however, it hasn’t mitigated other financial weaknesses. Iovance’s capability to achieve profitable growth hinges significantly on its operational and strategic realignment, given its unfavorable current financial health indicators.

Technical Analysis & Trading Strategy: The weekly price pattern of IOVA shows mild volatility with prices fluctuating from $2.19 to $2.4999, closing mainly around the $2.22-$2.47 range. The dominant trend appears sideways with minor bullish overtures, as the pattern traverses the lower band of its recent trading range. Currently, the stock’s liquidity signals through volume spikes suggest an accumulation phase. For traders, exploiting strategic entry near $2.20 with a cautious stop loss around $2.15 and targeting $2.49 aligns with technical formations and recent price actions. The alignment with historical resistance near $2.50 necessitates close monitoring for breakout potential or retracements.

Catalysts & Outlook: Recent developments highlight Health Canada’s approval of Amtagvi, providing Iovance with international expansion potential and reinforcing its commitment to innovative therapy commercialization. Despite earnings misses and a lowered price target from Wells Fargo to $14, there’s optimism reflected in Iovance’s sustained revenue guidance of $250M-$300M for FY25, propelled by growing Amtagvi sales and expanding Proleukin influence. Notwithstanding present challenges, including a declining stock price post-secondary offering announcement, the company’s prospects are buoyed by strategic advances and regulatory milestones. Market patience may be rewarded as Iovance navigates through growth phases, with price support identified around $2.20 and potential resistance near the $2.50 threshold. The sector comparison sheds light on IOVA’s room for managerial improvements relative to stronger peers in Biotechnology & Life Sciences, but with a cautiously optimistic trajectory due to its unique therapeutic propositions.

Candlestick Chart

Weekly Update Sep 01 – Sep 05, 2025: On Saturday, September 06, 2025 Iovance Biotherapeutics Inc. stock [NASDAQ: IOVA] is trending up by 12.3%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Iovance Biotherapeutics reported a Q2 EPS of $(0.33), which failed consensus estimates. This shortfall was largely driven by underperforming IL-2 revenue, contrasting with the strong uptake of Amtagvi in the treatment of advanced melanoma. The company has treated over 100 patients in a single quarter, indicating a promising trend for future revenue flows.

Their balance sheet reveals total assets of $907.44M, against $208.95M in liabilities, resulting in a debt-to-equity ratio of 0.08, indicating solid financial health and a stable position for further investment in R&D. Additionally, the current ratio of 3.3 demonstrates satisfactory liquidity, providing Iovance with a comfortable runway for continued clinical and market expansion efforts.

Furthermore, Iovance’s financial strategy includes a $350M secondary offering eyeing pipeline expansion and commercial reach, despite its anticipated dilutive impact. This decision aligns with their commitment to bolster their late-stage pipeline and strategic growth initiatives, reinforcing the positive sentiment despite short-term market volatility.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”